Generate Biomedicines, Inc. (NasdaqGS: GENB)
Health Care · Biotechnology · US
$17.72
+13.30% today · +23.6% 1Y
Generate Biomedicines, Inc. (NasdaqGS: GENB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.01B and employs 312 people.
Over the last twelve months the share price has gained 23.6%, trading between 11.00 and 18.18.
GENB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.01B
- Revenue (TTM)
- $26.48M
- P/E
- —
- EPS
- -3.28
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $18.18
- 52-week low
- $11.00
- Avg volume (3M)
- —
- Shares outstanding
- 128.35M
- Employees
- 312
- Next earnings
- —
About Generate Biomedicines, Inc.
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
- ISIN
- US3709201004
- Founded
- 2018
- Listed since
- Feb 27, 2026
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $138.89 | -4.26% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.